Scarica l'app Stockscreener
16.26
7.03%
-1.23
Dopo l'orario di chiusura:
16.26
Vtv Therapeutics Inc Borsa (VTVT) Ultime notizie
(VTVT) Trading Advice - news.stocktradersdaily.com
vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com - Defense World
(VTVT) Trading Signals - news.stocktradersdaily.com
vTv Therapeutics Inc Reports Q4 2024 EPS of -$0.55, Beating Esti - GuruFocus.com
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewswire
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
VTv Therapeutics: Q4 Earnings Snapshot - CTPost
VTv Therapeutics: Q4 Earnings Snapshot -March 20, 2025 at 06:02 pm EDT - Marketscreener.com
vTv Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FDA Greenlights vTv Diabetes Drug Trial as Cash Reserves Triple to $36.7M - StockTitan
vTv Therapeutics Inc. (VTVT) reports earnings - Quartz
Why Celsius Holdings Stock Popped This Week - The Globe and Mail
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More - Zacks Investment Research
Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Decreases By 13.6% - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Biotech Alert: Searches spiking for these stocks today - TipRanks
StockNews.com Begins Coverage on vTv Therapeutics (NASDAQ:VTVT) - Defense World
vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial - GuruFocus.com
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup - MarketScreener
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Sector Update: Health Care -March 17, 2025 at 03:39 pm EDT - Marketscreener.com
FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
FDA Lifts Clinical Hold, vTv Therapeutics (VTVT) Stock Surges - Stocks Telegraph
vTv Therapeutics up after FDA lifts clinical hold on its oral diabetes treatment study - Seeking Alpha
vTv Therapeutics resumes phase 3 diabetes trial By Investing.com - Investing.com Australia
VTv Therapeutics Says FDA Lifted Clinical Hold On Cadisegliatin Program For Diabetes - Nasdaq
vTv Therapeutics stock surges on FDA update By Investing.com - Investing.com Canada
Vtv Therapeutics Says FDA Lifts Clinical Hold on Cadisegliatin Program for Diabetes; Shares Up Pre-Bell - Marketscreener.com
vTv Therapeutics stock surges on FDA update - Investing.com
vTv Therapeutics resumes phase 3 diabetes trial - Investing.com
vTv Therapeutics Announces Resumption of CATT1 Phase 3 Trial for Cadisegliatin as Potential First Oral Adjunct Therapy for Type 1 Diabetes - Nasdaq
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes - The Manila Times
FDA Green Light: vTv's Revolutionary Oral Diabetes Drug Back on Track with Faster Timeline - StockTitan
3 Quality Compounders on Our Buy List - The Globe and Mail
vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga
vTv Therapeutics Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
vTv Therapeutics (VTVT) Projected to Post Quarterly Earnings on Tuesday - Defense World
Long Term Trading Analysis for (VTVT) - Stock Traders Daily
vTv Therapeutics CFO to Resign in March By Investing.com - Investing.com Canada
vTv Therapeutics CFO to Resign in March - Investing.com
vTv Therapeutics CFO Steven Tuch to Resign - TipRanks
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com - Defense World
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):